Platform
Company
Coagulation
Review status
Currently under review
Pending specialist review and validation.
The Factor XI Preliminary test measures how well factor XI, a clotting protein made in the liver, is working in your blood. It is a functional, clot-based assay performed on citrated plasma to estimate the activity of factor XI within the intrinsic coagulation pathway. This test is often ordered along with other clotting studies when there is unexplained bleeding, an abnormal activated partial thromboplastin time, a family history of factor deficiencies, or before surgery or dental work.
It is considered a screening assessment of factor XI function. If the result suggests a problem, your clinician may order confirmatory studies to clarify whether the issue is due to low levels, an inhibitor, or an effect from medications.
Factor XI plays a role in stabilizing clots, so reduced activity can increase the chance of bleeding, especially with surgery, dental procedures, or injuries to areas like the mouth and nose. Some people are born with a factor XI deficiency, sometimes called hemophilia C, while others may acquire low activity due to liver disease, immune inhibitors, or consumption during an acute illness. Knowing your factor XI activity helps tailor plans to prevent or control bleeding during procedures and in daily life.
Clinicians also consider medications that affect clot-based tests, because some anticoagulants can make factor activity appear lower than it truly is. In certain settings, higher factor XI activity has been linked to a tendency to form clots, but this is interpreted cautiously and alongside your history, examination, and other laboratory results.
Your result will be interpreted in the context of your symptoms, medications, and other coagulation tests. A result within the expected range suggests adequate factor XI function. A lower result may point to a congenital deficiency, an acquired inhibitor, liver-related reduction, or an artifact from anticoagulant drugs. Because clot-based methods can be affected by several conditions, repeat testing or additional studies are often used to confirm a finding.
If your level appears reduced, your clinician may consider a mixing study, inhibitor testing, or specific assays to sort out the cause. If you take blood thinners, the laboratory may use strategies to reduce drug interference or ask for a sample when the drug is at a low point. For people with confirmed deficiency, management around procedures may include antifibrinolytic medicines or factor replacement strategies, planned in consultation with a hematology specialist.
Always discuss next steps with your care team. They will decide whether to monitor, repeat the test, investigate further, or make a treatment plan tailored to your situation and any upcoming procedures.
Reference intervals vary by laboratory, analyzer, methodology, population, and units. The ranges shown here are for education only. Always interpret your results against the reference interval printed on your own lab report.
Underfilled citrate tubes, clotted samples, delayed processing, or extreme temperatures can invalidate the result. Hemolysis, lipemia, or high bilirubin may also interfere with clot-based measurements.
Heparins and direct oral anticoagulants can artifactually lower clot-based factor activity results. Warfarin may affect clotting assays indirectly. Tell your clinician about all medications and timing of your last dose.
Antiphospholipid antibodies or specific factor XI inhibitors can prolong clotting-based tests and mimic deficiency. Additional studies, such as mixing tests, help distinguish true deficiency from an inhibitor effect.
Newborns naturally have lower activity for some clotting factors, including factor XI. Physiologic changes during pregnancy can alter coagulation test results, so interpretation must consider these contexts.
Factor XI is produced in the liver, so liver impairment or consumptive coagulopathy can reduce activity. Acute illness or inflammation can also influence results and may warrant repeat testing after recovery.
Transfusion of plasma or use of factor concentrates can temporarily raise measured activity. Ideally, testing is performed before such therapy or with timing documented to aid accurate interpretation.
References